Incruse Ellipta (Umeclidinium Bromide) Patent Expiration, LOE Window & CMS Spending
Incruse Ellipta (Umeclidinium Bromide) by GSK: FDA Orange Book core substance LOE 2027-12-18, 0 AB generics, $436.8M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | GSK |
| FDA Application & Pathway | N205382 (NDA) |
| Exclusivity / Cliff Horizon | Immediate Cliff (2025-2027) |
| Core Active-Ingredient LOE Date | 2027-12-18 |
| Last Listed Patent or Exclusivity Date | 2027-12-18 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $436.8M |
| 2024 Medicare Part D Spend | $375.9M |
| 2024 Medicaid Spend | $60.9M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for GSK across sibling Meru public-data platforms.